Valuation: NOVARTIS

Market Cap 30TCr 26TCr 24TCr 22TCr 42TCr 28,36500Cr 42TCr 2,82800Cr 1,11100Cr 14,12900Cr 1,11700Cr 1,09200Cr 46,81000Cr P/E 2026 *
22.2x
P/E 2027 * 19x
Enterprise Value 33TCr 29TCr 27TCr 25TCr 46TCr 31,52400Cr 47TCr 3,14300Cr 1,23500Cr 15,70200Cr 1,24100Cr 1,21400Cr 52,02200Cr EV / Sales 2026 *
5.74x
EV / Sales 2027 * 5.32x
Free-Float
91.66%
Yield 2026 *
2.8%
Yield 2027 * 2.92%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-3.12%+51.15%+150.58% 1,03000Cr
+0.21%-1.13%+53.26%+46.92% 62TCr
-2.51%-2.33%+32.56%+66.35% 45TCr
+0.06%+1.17%+36.21%+31.25% 35TCr
-0.69%-0.44%+9.86%+14.23% 27TCr
-7.37%-4.31%-5.69%-41.99% 23TCr
-0.64%+3.68%+27.80%+62.95% 21TCr
-0.82%-0.50%+13.46%+69.41% 16TCr
+0.40%-.--%+5.04%-30.66% 14TCr
Average -0.88%+4.58%+24.85%+41.00% 38.4TCr
Weighted average by Cap. -0.38%+4.84%+35.60%+69.32%

Financials

2026 *2027 *
Net sales 5.76TCr 5TCr 4.65TCr 4.27TCr 8.07TCr 5,49200Cr 8.2TCr 55TCr 22TCr 2,73600Cr 22TCr 21TCr 9,06400Cr 6.11TCr 5.3TCr 4.94TCr 4.53TCr 8.57TCr 5,83000Cr 8.71TCr 58TCr 23TCr 2,90400Cr 23TCr 22TCr 9,62100Cr
Net income 1.38TCr 1.2TCr 1.11TCr 1.02TCr 1.93TCr 1,31400Cr 1.96TCr 13TCr 5.15TCr 65TCr 5.17TCr 5.06TCr 2,16900Cr 1.54TCr 1.33TCr 1.24TCr 1.14TCr 2.15TCr 1,46500Cr 2.19TCr 15TCr 5.74TCr 73TCr 5.77TCr 5.64TCr 2,41700Cr
Net Debt 3.31TCr 2.87TCr 2.67TCr 2.46TCr 4.64TCr 3,15800Cr 4.72TCr 31TCr 12TCr 1,57300Cr 12TCr 12TCr 5,21200Cr 2.78TCr 2.41TCr 2.25TCr 2.06TCr 3.9TCr 2,65300Cr 3.96TCr 26TCr 10TCr 1,32200Cr 10TCr 10TCr 4,37800Cr
Logo NOVARTIS
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA